The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw

About this episode

Allan Shaw discusses the unpredictability of FDA decision-making and its impact on biotech.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, five-time public company CFO and seven-time public company board member Allan Shaw talks about why FDA decision-making feels less predictable, and how that uncertainty is reshaping clinical trial strategy, investor behavior, and the innovation ecosystem. We talk about FDA politicization concerns, modernization efforts like AI initiatives, and what biotech leaders can do to manage risk in...

People in this episode

Host: Ben Comer

Guest: Allan Shaw

Topics covered

• FDA decision-making
• clinical trial strategy
• investor behavior
• biotech innovation
• risk management

Keywords

• FDA
• biotech
• clinical trials
• risk
• investors
• innovation
• AI

Mentioned in this episode

Organizations: FDA

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D. · June 1, 2026 · 50 min
• Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane · May 25, 2026 · 55 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min
• From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. · May 4, 2026 · 56 min